Analyst Ratings February 19, 2026

Barclays Lowers Rating on BASF, Cites Valuation and Weak Operating Signals

Analyst firm trims stance to Underweight and sets EUR40 target, flagging limited upside amid subdued fundamentals

By Marcus Reed BASFY
Barclays Lowers Rating on BASF, Cites Valuation and Weak Operating Signals
BASFY

Barclays has downgraded BASF SE to Underweight from Equalweight and assigned a EUR40.00 price target, pointing to valuation that presumes a recovery not yet visible in operating results. The bank’s updated forecasts incorporate modest 2026 growth and lower adjusted EBITDA estimates, and it highlights the company’s recent fiscal 2025 profit warning and cautious near-term commentary as reasons to temper expectations.

Key Points

  • Barclays downgraded BASF from Equalweight to Underweight and set a EUR40.00 price target.
  • The bank cites a P/E ratio of 143.76 and a 21% one-year price return as part of its valuation concern, noting the market assumes a recovery not yet visible in operating results.
  • Barclays forecasts 1% year-over-year growth for 2026 with adjusted EBITDA of EUR7.2 billion including Coatings and EUR6.82 billion excluding Coatings; earnings are due on February 27 in 8 days.

Barclays cut its recommendation on BASF SE to Underweight from Equalweight on Thursday and established a price target of EUR40.00, pointing to what it describes as stretched valuation and underwhelming operating performance.

The bank highlighted the stock’s current price-to-earnings ratio of 143.76 as a focal point for its valuation concerns, even as BASF has returned 21% in share price over the previous year. Barclays said that the market appears to be pricing in a cyclical recovery and a liquidity-driven premium that, in its view, are not supported by the company’s operating results to date.

Supporting that view, InvestingPro data cited by analysts shows BASF trading above its Fair Value and on the overvalued side. Barclays noted that while recent policy-related headlines tied to ETS have lent some support to market sentiment, the firm sees little evidence in the underlying fundamentals of a sustained turnaround in earnings.

The downgrade follows BASF’s fiscal 2025 profit warning, which Barclays says implies the weakest fourth-quarter exit rate the company has posted in a decade. In response, the bank revised its forecasts to assume modest year-over-year growth of 1% for 2026. Barclays’ updated projections call for adjusted EBITDA of EUR7.2 billion including Coatings and EUR6.82 billion excluding Coatings.

Barclays also observed that the firm’s estimates sit roughly 3% below company consensus. The analyst house pointed to the combination of BASF’s fourth-quarter profit warning, cautious commentary on the first quarter, and muted guidance from peers as factors that offer limited support for a near-term recovery in results.

Investors should note that BASF is scheduled to report earnings in 8 days on February 27, a milestone Barclays suggests could provide additional clarity on the company’s outlook. According to the bank, the EUR40.00 price target implies approximately 20% downside from current levels.


Contextual note: The views and figures above reflect Barclays’ analysis and revised forecasts as described by the firm.

Risks

  • Persistently weak operating results - continued underperformance in fundamentals could keep pressure on BASF’s share price and valuation, affecting the chemicals and industrials sectors.
  • Earnings uncertainty around the near-term reports - upcoming earnings on February 27 could fail to clarify the outlook, increasing volatility in equities and related markets.
  • Macroeconomic/sector peer weakness - subdued guidance from peers and cautious commentary may limit prospects for a synchronized recovery across chemicals and industrial inputs.

More from Analyst Ratings

DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 BWS Financial Boosts A10 Networks Price Target Citing AI-Driven Network Traffic Feb 20, 2026